No­var­tis’ ra­dio­phar­ma gam­bit; Weight loss bat­tle plays out; Spark co-founder’s new start­up; Q1 earn­ings high­lights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We are less than two weeks away from the US Phar­ma and Biotech Sum­mit, where we part­ner with the Fi­nan­cial Times to in­ter­view bio­phar­ma lead­ers, reg­u­la­tors, in­vestors and sci­en­tists for unique in­sights about the year ahead. Learn more and sign up here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER